Physician profile
Walter Young
NPI 1356301055
$1,309.65
in general payments reported to CMS, 2019-2025
18 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $71.37 · 2021: $209 · 2022: $307 · 2023: $162 · 2024: $189 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.36 | 2020-2025 | |
| Braintree Laboratories, INC. | $198.44 | 2019-2021 | |
| Genzyme Corporation | $105.33 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.74 | 2022-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $86.43 | 2022-2025 | Entyvio |
| Celltrion USA INC. | $81.42 | 2025 | Vegzelma |
| Celgene Corporation | $62.67 | 2021-2023 | Zeposia |
| Lucid Diagnostics INC. | $45.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $42.87 | 2023 | Dupixent |
| Lilly USA, LLC | $25.39 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $23.56 | 2019 | |
| Pfizer INC. | $21.40 | 2025 | |
| Qol Medical, LLC | $20.87 | 2021 | |
| Amgen INC. | $16.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $15.92 | 2022 | |
| Vivus LLC | $13.80 | 2024 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,114.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.